Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.

Publication Type:

Journal Article

Authors:

Ravandi, Farhad; Estey, Eli; Jones, Dan; Faderl, Stefan; O'Brien, Susan; Fiorentino, Jackie; Pierce, Sherry; Blamble, Deborah; Estrov, Zeev; Wierda, William; Ferrajoli, Alessandra; Verstovsek, Srdan; Garcia-Manero, Guillermo; Cortes, Jorge; Kantarjian, Hagop

Source:

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 27, Issue 4, p.504-10 (2009)

Keywords:

Adolescent, Adult, Aged, Aged, 80 and over, Aminoglycosides, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Arsenicals, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Leukemia, Promyelocytic, Acute, Male, Middle Aged, Oxides, Polymerase Chain Reaction, Remission Induction, Survival Rate, Treatment Outcome, Tretinoin

Abstract:

We examined the outcome of patients with newly diagnosed acute promyelocytic leukemia (APL) treated with all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) with or without gemtuzumab ozogamicin (GO) but without traditional cytotoxic chemotherapy.